Ob/Gyn Group Urges Pregnant Women to Shun Paxil

Birth defect risk must be balanced against need for depression treatment, experts say

By Amanda Gardner
HealthDay Reporter

Related Encyclopedia • Acne • AIDS and HIV Infection • Alagille Syndrome • Amenorrhea More... Related Healthscout Videos Preventing Breast Cancer Tracking Breast Cancer Treatment Easier Radiation for Breast Cancer Fighting HIV More... Related Animations • Bipolar Disorder Animation • Breast Reduction • Breast Self-Exam Video • Dental Cavities More... Related Drug Information • Actonel • Adderal XR • Ambien • Avandia More... Related News Articles • Health Tip: Fluid in the Ear • Health Tip: Emotional Reasons for Erectile Dysfunction • Fetal Exposure to Arsenic Affects Genes • Health Tip: Make the Holidays More Meaningful More...

WEDNESDAY, Nov. 29 (HealthDay News) -- A group representing America's obstetricians is recommending that women avoid the antidepressant Paxil if they are pregnant or planning on becoming pregnant, due to a potential heightened risk for birth defects.

The American College of Obstetricians and Gynecologists (ACOG) also cautioned that treatment with other antidepressants should be considered on a case-by-case basis.

Text Continues Below

---

ACOG's Committee on Obstetric Practice "recommends that treatment with all SSRIs [selective serotonin reuptake inhibitors] or selective norepinephrine reuptake inhibitors or both during pregnancy be individualized and paroxetine [Paxil] use among pregnant women or women planning to become pregnant be avoided, if possible," read the statement, which is in the December issue of Obstetrics & Gynecology.

The guidelines come a full year after the U.S. Food and Drug Administration (FDA) issued a warning about possible birth defects associated with Paxil when the drug is taken during the first trimester of pregnancy.

This warning was based on two studies. The first found about a 2 percent risk of heart defects in babies born to mothers who took Paxil early in their pregnancy, compared with a 1 percent risk in the general population.

The second study found that the risk of heart defects was 1.5 percent in babies whose mothers took Paxil in the first three months of pregnancy, compared with 1 percent in babies whose mothers took other antidepressants in the first trimester. The most common defects were cardiovascular.

"Since the FDA warnings a year ago, most ob/gyns have been trying to avoid Paxil during pregnancy," noted Dr. Jennifer Wu, an obstetrician/gynecologist at Lenox Hill Hospital in New York City. "This is just a formal statement by ACOG."

The initial FDA warning came in September of 2005. In December of the same year, the FDA instructed Paxil's maker, GlaxoSmithKline, to reclassify the drug from a Category C to D (a stronger warning) for pregnant women. Category D means studies in pregnant women have demonstrated a risk to the fetus.

Page:  1 | 2 | Next >>